Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures

Abstract

Recent studies indicate that selective noradrenergic (atomoxetine) and serotonergic (citalopram) reuptake inhibitors may improve response inhibition in selected patients with Parkinson's disease, restoring behavioral performance and brain activity. We reassessed the behavioral efficacy of these drugs in a larger cohort and developed predictive models to identify patient responders. We used a double‐blind randomized three‐way crossover design to investigate stopping efficiency in 34 patients with idiopathic Parkinson's disease after 40 mg atomoxetine, 30 mg citalopram, or placebo. Diffusion‐weighted and functional imaging measured microstructural properties and regional brain activations, respectively. We confirmed that Parkinson's disease impairs response inhibition. Overall, drug effects on response inhibition varied substantially across patients at both behavioral and brain activity levels. We therefore built binary classifiers with leave‐one‐out cross‐validation (LOOCV) to predict patients’ responses in terms of improved stopping efficiency. We identified two optimal models: (1) a “clinical” model that predicted the response of an individual patient with 77–79% accuracy for atomoxetine and citalopram, using clinically available information including age, cognitive status, and levodopa equivalent dose, and a simple diffusion‐weighted imaging scan; and (2) a “mechanistic” model that explained the behavioral response with 85% accuracy for each drug, using drug‐induced changes of brain activations in the striatum and presupplementary motor area from functional imaging. These data support growing evidence for the role of noradrenaline and serotonin in inhibitory control. Although noradrenergic and serotonergic drugs have highly variable effects in patients with Parkinson's disease, the individual patient's response to each drug can be predicted using a pattern of clinical and neuroimaging features. Hum Brain Mapp 37:1026–1037, 2016. © 2016 Wiley Periodicals, Inc.

Brain signature and functional impact of centralized pain: a multidisciplinary approach to the study of chronic pelvic pain (MAPP) network study

“…The clinical need for tests that enable diagnoses and treatment decisions based on objective criteria, in addition to patient self-report, has also been highlighted [4; 49]. While the current state of the field precludes the use of brain imaging in the diagnosis and treatment of chronic pain patients, current trends in other neurobiological disorders suggests that objective MRI outcomes may provide useful future information to assist in clinical decisions [19; 21; 57]. For example, brain MRI outcomes could be used to predict, at the individual patient level, who would benefit from a specific treatment.…”

Drug Repositioning for Parkinson�s Disease Based on Adverse Drug Reactions Detected from Social Media (Preprint)

“…As recent research indicates that selective noradrenergic (atomoxetine) and serotonergic (citalopram) reuptake inhibitors is potential to improve response inhibition on some PD patients, a double-blind experiment was conducted to investigate the behavioral efficacy of citalopram and atomoxetine [23]. Results supported the hypothesis that they are effective in inhibitory control.…”

Cognitive deficits in Parkinson’s disease: current perspectives

“…58 Recent work has shown that it is possible to predict whether atomoxetine and citalopram will affect impulsivity, as measured by response inhibition, using a combination of clinical, structural and functional imaging. 59 There is some evidence of downregulation of serotonin receptors associated with cognition in PD, although no association with executive function was found. 60 …”